Core Viewpoint - The company plans to issue a total of 221.5 million subscription shares, representing approximately 12.12% of the enlarged issued share capital after the issuance, at a subscription price of HKD 0.10 per share, which is a premium of about 44.93% over the closing price of HKD 0.069 on July 29 [1] Financial Summary - The total amount expected to be raised from the subscription is approximately HKD 22.15 million, with a net amount of about HKD 22.02 million [1] - The net proceeds from the subscription are intended to be used for the repayment of overdue lease payments and other outstanding bond payments due within three months from the announcement date, amounting to approximately HKD 13.2 million, and for general working capital of approximately HKD 8.8 million [1]

于7月29日根据股份购买协议拟以每股对价股份12港元的发行价格，根据一般授权分配及发行总计 198.55万股对价股份。 药师帮(09885)发布公告，于7月8日至7月29日，根据公司于2019年1月1日采纳的2019年股份激励计划， 因行使所获授予的购股权发行合共56.04万股股份。 ...

Group 1 - The company, Pioneer Pharmaceuticals (00399), has entered into subscription agreements with two investors, A and B, to issue a total of 90 million shares at a subscription price of HKD 0.312 per share, which represents a discount of approximately 20% compared to the closing price of HKD 0.39 on the date of the agreements [1][2] - The shares subscribed by Investor A will account for approximately 3.00% of the company's existing issued share capital as of the announcement date, while the shares subscribed by Investor B will account for approximately 1.50% [1] - The total gross proceeds from the subscription will be approximately HKD 28.08 million, with a net amount of approximately HKD 27.78 million, intended for general working capital of the group [2] Group 2 - The board of directors believes that the current market conditions present a good opportunity for the company to strengthen its capital base and financial position through the issuance of subscription shares [2] - The issuance of subscription shares is considered an appropriate means to raise additional funds, as the subscription price is lower than the market price, which was reached after fair negotiations with the investors [2]

Group 1 - The company announced agreements with various subscribers to issue a total of 19.34 million shares at a subscription price of approximately HKD 0.04801 per share [1] - The company also entered into agreements to issue convertible bonds amounting to HKD 15 million each to three different subscribers, with a conversion price of HKD 0.04801 per share [2] - The total gross proceeds from the subscription are approximately HKD 2.79 million, with a net amount of approximately HKD 2.52 million, which will be used to repay group debts and provide working capital [2] Group 2 - The board believes that raising funds through the subscription is reasonable given the recent market conditions, and it provides an opportunity to enhance the company's working capital and financial position [2] - The subscription not only offers fundraising opportunities but also expands the company's shareholder base and capital foundation [2]

Core Points - The company, JOINN LABORATORIES (CHINA) CO., LTD., was established on December 26, 2012, and is registered in the Beijing Economic and Technological Development Zone [2] - The company was approved by the China Securities Regulatory Commission (CSRC) to issue H shares on August 4, 2017, and subsequently listed on the Hong Kong Stock Exchange [2][3] - The registered capital of the company is RMB 749.34822 million [2][3] - The company aims to provide a new drug research and development technology platform for domestic and foreign enterprises, accelerating the industrialization of scientific and technological achievements [5] Company Structure - The company is a permanent joint-stock company, with all assets divided into equal shares, and shareholders are liable only to the extent of their subscribed shares [3] - The company has a total of 270,820,329 shares, with 63,035,301.4 million shares held by domestic investors, accounting for approximately 84.12% of the total share capital, and 11,899,520.6 million H shares held by foreign investors, accounting for approximately 15.88% [9] - The company can issue ordinary shares and, with approval, can also issue other types of shares [6][9] Share Issuance and Management - The company issues shares based on principles of openness, fairness, and justice, ensuring that each share of the same type has equal rights [6] - The company can increase its capital through various methods, including public offerings, private placements, and bonus shares [10] - The company has the right to repurchase its shares under specific circumstances, such as reducing registered capital or merging with other companies [11][12] Shareholder Rights - Shareholders have the right to receive dividends, attend and vote at shareholder meetings, supervise the company's operations, and transfer their shares [28] - The company must maintain a shareholder register that includes details of each shareholder and their respective shareholdings [22][25] - Shareholders can request the company to repurchase their shares if they disagree with resolutions made at shareholder meetings [28]

晶澳太阳能科技 股份有限公司 章程（草案） | | 英文全称：JA Solar Technology Co., Ltd. | | --- | --- | | 第4条 第5条 | 公司注册名称：晶澳太阳能科技股份有限公司 公司住所：河北省宁晋县新兴路 号 123 | 邮政编码：055550 （H 股发行并上市后适用） | 第一章 | 总 则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股 份 | 3 | | | 第一节 股份发行 | 3 | | 第二节 | 股份增减和回购 | 5 | | 第三节 | 股份转让 | 7 | | 第四章 | 股东和股东大会 | 7 | | 第一节 | 股东 | 8 | | 第二节 | 股东大会的一般规定 | 10 | | 第三节 | 股东大会的召集 | 15 | | | 第四节 股东大会的提案与通知 | 16 | | 第五节 | 股东大会的召开 | 17 | | 第六节 | 股东大会的表决和决议 | 20 | | 第五章 | 董事会 | 23 | | 第一节 | 董事 | 23 | | 第二节 | 独立董事 | 2 ...